Why the study?
Trial data have been inconsistent regarding the cardiovascular and kidney benefits of intensive blood pressure lowering, and evidence for newer therapies remains limited in advanced chronic kidney disease.
Does intensive blood pressure lowering and use of newer antihypertensive agents improve cardiorenal outcomes in patients with advanced chronic kidney disease?
Population
Patients with advanced chronic kidney disease and hypertension
Design
Review
Key result
Newer antihypertensive therapies have proven cardiorenal benefits, but evidence for intensive blood pressure lowering remains limited in patients with advanced chronic kidney disease.
Authors
Loading...
Intensive BP lowering in advanced CKD lacks consistent trial support; leaves open optimal targets for practice and dedicated RCTs.
Does intensive blood pressure lowering and use of newer antihypertensive agents improve cardiorenal outcomes in patients with advanced chronic kidney disease?
While newer antihypertensive therapies offer proven cardiorenal benefits, further studies are needed to establish their safety and efficacy specifically in patients with advanced chronic kidney disease.
Tantisattamo et al. (2026) conducted a review in Hypertension in advanced chronic kidney disease. Intensive blood pressure lowering and newer antihypertensive therapies was evaluated. Newer antihypertensive therapies have proven cardiorenal benefits, but evidence for intensive blood pressure lowering remains limited in patients with advanced chronic kidney disease.